


We claim:

1. A compound, having a formula



- 5 or a pharmaceutically acceptable salt thereof, wherein:

ring B is 5-membered heteroaryl;

L is a C₁₋₁₀ aliphatic linker;

R¹ is R^a or R^b wherein at least one R¹ is R^b;

each of R² and R³ independently are R^a;

- 10 each R⁴ and each R⁵ independently are R^a or R^b;

R^a is independently for each occurrence H, D, C₁₋₁₀ aliphatic, or C₁₋₁₀ cycloaliphatic;

R^b is independently for each occurrence halogen or -NR^dR^d wherein (i) each R^d independently is R^a or R^e; or (ii) two R^d groups together with the nitrogen bound thereto provide a C₃₋₁₀ heterocyclic group;

- 15 R^e is independently for each occurrence -OR^a, -NR^a, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ heteroalkyl, C₃₋₆ cycloalkyl, or two R^e groups join together to provide a C₃₋₁₀ heterocyclic group


with the R^b group to which the two R^e groups are bound;

m is 1 to 4;

n is 0, 1 or 2; and

- 20 p is 0, 1, 2, 3, 4, or 5.


2. The compound of claim 1, wherein the compound has a structure satisfying a formula




- 25 3. The compound of claim 1 or claim 2, wherein ring B has a structure satisfying a

formula , wherein at least one W is nitrogen, and each remaining W independently is selected from carbon, CH, oxygen, sulfur, nitrogen, or NH.

4. The compound of any one of claims 1-3, wherein ring B is a triazole selected from



or an oxazole selected from



5. The compound of any one of claims 1-4, wherein R^5 is R^a , wherein R^a is C_1 - C_4 aliphatic, or R^5 is R^b , wherein R^b is halogen; and/or wherein R^2 is R^a wherein R^a is C_1 - C_4 aliphatic and R^3 is R^a , wherein R^a is hydrogen.

5

6. The compound of any one of claims 1-5, wherein R^1 is R^b wherein R^b is $-NR^dR^d$ wherein two R^d groups together with the nitrogen bound thereto provide a C_{3-10} heterocyclic group comprising two R^e groups that join together to provide a second C_{3-10} heterocyclic group.

10

7. The compound of claim 6, wherein the second C_{3-10} heterocyclic formed by the two R^e groups and the C_{3-10} heterocyclic formed by the two R^d groups of R^b provide a spirocyclic group or a bicyclic group.

15

8. The compound of claim 6 or claim 7, wherein the spirocyclic group comprises at least two rings, wherein a first ring and a second ring of the spirocyclic group have a different number of carbon atoms, a different number of heteroatoms, or both and wherein each ring of the spirocyclic group comprises a heteroatom in the ring.

20

9. The compound of any one of claims 6-8, wherein the spirocyclic group comprises at least one oxygen atom and at least one nitrogen atom.

25


10. The compound of any one of claims 6-9, wherein the spirocyclic group comprises a first ring coupled to a carbon atom of the compound, the first ring having from 3 to 7 atoms and a second ring having from 3 to 7 atoms.

11. The compound of any one of claims 6-10, wherein the spirocyclic group comprises greater than 7 total atoms in the spirocyclic system.

12. The compound of any one of claims 6-11, wherein the C_{3-10} heterocyclic formed by the two R^e groups and the C_{3-10} heterocyclic formed by the two R^d groups of R^b provide a bicyclic group and the bicyclic group comprises two or more heteroatoms in the bicyclic group.

5 13. The compound of claim 12, wherein the bicyclic group is a fused bicyclic group or a bridged bicyclic group and wherein the bicyclic group is attached to the ring A phenyl group of Formula I through a nitrogen atom of the bicyclic group.


14. The compound of any one of claims 1-13, wherein R^1 is






wherein each n independently is an integer ranging from 0 to 4 and R⁶ independently is selected from hydrogen, aliphatic, aromatic, or heteroaliphatic.


15. The compound of any one of claims 1-14, wherein the compound is selected from




I-1;




I-2;




I-3;




I-4;




I-5;




I-6;




I-7;




I-8;




I-9;




I-10;




I-11;




I-12;




I-13;




I-14;




I-15;




I-16;




I-17;




I-18;




I-19;




I-20;




I-21;




I-22;




I-23;




I-24;



I-25;




I-26; or



I-27.

16. The compound of any one of claims 1-15, wherein the compound is




17. A pharmaceutical composition, comprising a compound according to any one of claims 1-15, an excipient, a therapeutic agent, an adjuvant, or combinations thereof.

18. A method, comprising contacting a receptor-interacting protein-1 (RIP1) kinase with a compound according to any one of claims 1-15, or the pharmaceutical composition of claim 17.


19. A method for treating a disease in a subject, comprising administering to the subject (i) a therapeutically effective amount of the compound of any one of claims 1-15, or a pharmaceutically acceptable salt, a stereoisomer, an N-oxide, a tautomer, a hydrate, a solvate, an isotope, or a prodrug thereof; or (ii) a therapeutically effective amount of a pharmaceutical composition of claim 16; wherein the subject has, or is suspected of having or developing, the disease, wherein the disease is a disease involving a receptor-interacting protein-1 (RIP1) kinase.

20. A method for making the compound of any one of claims 1-15, comprising:
coupling a starting material having a Formula A with an R^1 -containing reagent having a formula R^1 -H, by combining the starting material and the R^1 -containing reagent with a transition metal catalyst, a ligand component, and a solvent to form an R^1 -functionalized product;
deprotecting an amine group of the R^1 -functionalized product to provide an amine compound; and
forming an amide bond between the amine compound and an acid-containing coupling partner;
wherein Formula A is




Formula A;

the R^1 -functionalized product has a structure satisfying Formula B



Formula B;

and the acid-containing coupling partner has a structure satisfying Formula C



Formula C; and wherein

X is a halogen or a triflate;

5 PG is an amine protecting group;

and each of ring B, L, R¹, R², R⁴, R⁵, m, n, and p are as recited for claim 1.

21. The method of claim 20, wherein the amide bond is formed by coupling the amine
compound and the acid-containing coupling partner in the presence of propylphosphonic anhydride and
10 diisopropylethylamine.